Table 4.
Molecular-targeted therapy of esophageal cancer
| Design | Treatment | n | RR | Median OS | Reference |
|---|---|---|---|---|---|
| Phase II (2nd line) | Erlotinib | 44++ | 9% | 6.7 months | 108 |
| Phase II (2nd line) | Gefitinib | 36+++ | 3% | 5.5 months | 109 |
| Phase II (1st/2nd) | Gefitinib | 27++ | 11% | 4.5 months | 110 |
| Phase II | Irinotecan/5-FU/cetuximab | 38++,# | 44%# | 16 months# | 67 |
| Phase II | Cisplatin/5-FU/cetuximab versus cisplatin/5-FU | 32+ | 19% | 9.5 months | 69 |
| 30+ | 13% | 5.5 months | |||
| Phase II | Cisplatin/docetaxel/cetuximab | 13++ | 41%# | 9 months | 65 |
| Phase II | Oxaliplatin/5-FU/cetuximab | 25++ | 77% | 9.5 months# | 68 |
| Phase II (2nd line) | Cetuximab | 55++ | 6% | 4.0 months | 105 |
| Phase III | 5-FU (capecitabine)/cisplatin ± trastuzumab | 58++ 48++ | 47%# 35%# | 13.8#,** 11.1# | 75 |
| Phase II (2nd line) | Cetuximab/irinotecan | 50++ | 14% | 5.5 months | 106 |
| Phase II (2nd line) | Erlotinib | 13+ | 15% | 8.2 months | 107 |
| 17++ | 0% | 11.2 months | |||
| Phase II (2nd line) | Cetuximab | 35++ | 3% | 3.1 months | 104 |
| Phase II | Irinotecan/5-FU/cetuximab | 13++ | 46%# | 16.5 months# | 66 |
| Phase II | 5-FU/oxaliplatin/erlotinib | 33++ | 52% | 11.0 months | 72 |
| Phase II/III | Epirubicin/oxaliplatin/capecitabine ± panitumumab | 278# 275# | 46% 42%# | 8.8 months# 11.3 months# | 71 |
| Phase II | Lapatinib | 16++ | 6% | NA | 76 |
| Phase III (2nd line) | Ramucirumab | 238++,# | 3.4%# | 5.2 months#,** | 111 |
| BSC | 117++,# | 2.6%# | 3.8 months# |
Notes:
**
P <0.01
+
squamous cell carcinoma
++
adenocarcinoma
+++
squamous cell carcinoma/adenocarcinoma
#
including gastric cancer patients.
Abbreviations: 5-FU, 5-fluorouracil; BSC, best supportive care; NA, non-applicable; RR, response rate; OS, overall survival.